Linked Life Data

16283378

Source:http://linkedlifedata.com/resource/pubmed/id/16283378

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16283378rdf:typepubmed:Citationlld:pubmed
pubmed-article:16283378lifeskim:mentionsumls-concept:C0208804lld:lifeskim
pubmed-article:16283378lifeskim:mentionsumls-concept:C0699885lld:lifeskim
pubmed-article:16283378lifeskim:mentionsumls-concept:C0079419lld:lifeskim
pubmed-article:16283378lifeskim:mentionsumls-concept:C1422009lld:lifeskim
pubmed-article:16283378lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:16283378lifeskim:mentionsumls-concept:C1441616lld:lifeskim
pubmed-article:16283378lifeskim:mentionsumls-concept:C1519522lld:lifeskim
pubmed-article:16283378lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:16283378lifeskim:mentionsumls-concept:C0868928lld:lifeskim
pubmed-article:16283378lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:16283378lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:16283378pubmed:issue3lld:pubmed
pubmed-article:16283378pubmed:dateCreated2006-3-9lld:pubmed
pubmed-article:16283378pubmed:abstractTextP63 is a member of the p53 family, which plays a role in the differentiation of urothelium and is supposed to play a role in urothelial carcinogenesis. P53 and MIB-1 are recognised in many studies as predictive markers of progression, but few studies in the literature have examined p63. The aims of our study were to explore the expression of p63 in bladder carcinomas and to compare this expression to p53 and MIB-1, as well as to stage and grade. Tissue microarrays were performed on 158 urothelial carcinomas (56 pTa, 45 pT1 and 57>or=pT2). Immunohistochemical studies were performed with p63, p53 and MIB-1 antibodies. In our study we observed that p63 immunostaining is present in all cell layers in papillary urothelial neoplasm of low malignant potential (PUNLMP), but partially lost in non-invasive papillary urothelial carcinoma low grade (NILGC) and in pT1/>or=pT2 bladder cancers. P53 and MIB-1 displayed lower expression in PUNLMP/NILGC vs non-invasive papillary urothelial carcinoma high grade (NIHGC)/pT1, but there was no correlation between the expression of p63, p53 and MIB-1. Our study demonstrates that p63 expression distinguishes between PUNLMP/NILGC and NIHGC/pT1 (p=4.10(5)). A statistical difference disserving pTa and pT1/>or=pT2 with a statistical significance (p<10(-6)) could also be observed. P63 should be considered as an additional biomarker that might help pathologists to classify their patients.lld:pubmed
pubmed-article:16283378pubmed:languageenglld:pubmed
pubmed-article:16283378pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16283378pubmed:citationSubsetIMlld:pubmed
pubmed-article:16283378pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16283378pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16283378pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16283378pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16283378pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16283378pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16283378pubmed:statusMEDLINElld:pubmed
pubmed-article:16283378pubmed:monthMarlld:pubmed
pubmed-article:16283378pubmed:issn0945-6317lld:pubmed
pubmed-article:16283378pubmed:authorpubmed-author:HoulgatteAlai...lld:pubmed
pubmed-article:16283378pubmed:authorpubmed-author:Chartier-Kast...lld:pubmed
pubmed-article:16283378pubmed:authorpubmed-author:DelcourtAnnic...lld:pubmed
pubmed-article:16283378pubmed:authorpubmed-author:RichardFranço...lld:pubmed
pubmed-article:16283378pubmed:authorpubmed-author:VieillefondAn...lld:pubmed
pubmed-article:16283378pubmed:authorpubmed-author:CamparoPhilip...lld:pubmed
pubmed-article:16283378pubmed:authorpubmed-author:CompératEvaElld:pubmed
pubmed-article:16283378pubmed:authorpubmed-author:HausRachelRlld:pubmed
pubmed-article:16283378pubmed:authorpubmed-author:BartStephaneSlld:pubmed
pubmed-article:16283378pubmed:authorpubmed-author:CapronFréderi...lld:pubmed
pubmed-article:16283378pubmed:issnTypePrintlld:pubmed
pubmed-article:16283378pubmed:volume448lld:pubmed
pubmed-article:16283378pubmed:ownerNLMlld:pubmed
pubmed-article:16283378pubmed:authorsCompleteYlld:pubmed
pubmed-article:16283378pubmed:pagination319-24lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:meshHeadingpubmed-meshheading:16283378...lld:pubmed
pubmed-article:16283378pubmed:year2006lld:pubmed
pubmed-article:16283378pubmed:articleTitleImmunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases.lld:pubmed
pubmed-article:16283378pubmed:affiliationService Central d'Anatomie et Cytologie Pathologiques et d'Urologie, Hôpital La Pitié-Salpêtrière, 83, Bd de l'Hôpital, 75013 Paris, France. evacomperat@yahoo.frlld:pubmed
pubmed-article:16283378pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:8626entrezgene:pubmedpubmed-article:16283378lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:16283378lld:entrezgene